文献速递胰腺与胆道疾病消化内镜

胆道梗阻患者内镜逆行胰胆管造影预防性抗生素随机试验

Randomized Trial of Prophylactic Antibiotics for Endoscopic Retrograde Cholangiopancreatography in Patients With Biliary Obstruction.
PubMed 文献 · Am J Gastroenterol · 2023-09-15

这项双盲、安慰剂对照随机试验纳入378例胆道梗阻患者,按1:1分配至ERCP前30分钟单次静脉注射头孢西丁1g组或生理盐水安慰剂组,评估预防性抗生素能否降低ERCP后感染并发症。结果显示抗生素组感染并发症风险2.8%,安慰剂组9.8%(RR 0.29,95%CI 0.11-0.74,P=0.0073),胆管炎发生率亦降低,菌血症发生率两组无显著差异。

要点

  • 胆道梗阻患者ERCP前30分钟单次静脉头孢西丁1g可降低ERCP后感染并发症风险。
  • 抗生素组感染并发症2.8% vs 安慰剂组9.8%(RR 0.29,95%CI 0.11-0.74,P=0.0073)。
  • 胆管炎发生率抗生素组1.7% vs 安慰剂组6.4%(RR 0.27,95%CI 0.08-0.87,P=0.0267)。

核心结论

  • 胆道梗阻患者ERCP前预防性使用抗生素可显著降低ERCP后感染并发症风险,尤其是胆管炎,优于安慰剂。

研究设计与样本

  • 双盲、安慰剂对照随机试验,纳入378例胆道梗阻患者,按1:1随机分配至ERCP前30分钟单次静脉注射头孢西丁1g组或生理盐水安慰剂组,每组189例。

主要发现

  • 抗生素预防组ERCP后感染并发症风险为2.8%(176例中5例),安慰剂组为9.8%(173例中17例),风险比0.29(95%CI 0.11-0.74,P=0.0073)。
  • 菌血症发生率抗生素组为2.3%(176例中4例),安慰剂组为6.4%(173例中11例),风险比0.36(95%CI 0.12-1.04,P=0.0599),未达统计学显著。
  • 胆管炎发生率抗生素组为1.7%(176例中3例),安慰剂组为6.4%(173例中11例),风险比0.27(95%CI 0.08-0.87,P=0.0267)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The incidence of postendoscopic retrograde cholangiopancreatography (ERCP) infections is reported to be up to 18% in patients with biliary obstruction. Antibiotic prophylaxis may reduce the risk of infectious complications after ERCP; however, the clinical value of prophylactic antibiotics in ERCP remains controversial. METHODS: We conducted a double-blind, placebo-controlled, randomized trial to investigate whether the use of prophylactic antibiotics would reduce infectious complications after ERCP in patients with biliary obstruction. We randomly assigned patients in a 1:1 ratio to receive either a single dose of 1 g intravenous cefoxitin or normal saline as a placebo 30 minutes before undergoing ERCP. The primary outcome was the incidence of infectious complications after ERCP. RESULTS: We enrolled 378 patients, and 189 patients were assigned to each group. The risk of infectious complications after ERCP was 2.8% (5 of 176 patients) in the antibiotic prophylaxis group and 9.8% (17 of 173 patients) in the placebo group (risk ratio, 0.29; 95% confidence interval [CI], 0.11-0.74, P = 0.0073). The incidence rates of bacteremia were 2.3% (4 of 176 patients) and 6.4% (11 of 173 patients), respectively (risk ratio, 0.36; 95% CI, 0.12-1.04; P = 0.0599). The incidence rate of cholangitis was 1.7% (3 of 176 patients) in the antibiotic prophylaxis group and 6.4% (11 of 173 patients) in the placebo group (risk ratio, 0.27; 95% CI, 0.08-0.87; P = 0.0267). DISCUSSION: Antibiotic prophylaxis before ERCP in patients with biliary obstruction resulted in a significantly lower risk of infectious complications, especially cholangitis, than placebo ( ClinicalTrials.gov trial number NCT02958059).

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Leem G, Sung MJ, Park JH, et al. Randomized Trial of Prophylactic Antibiotics for Endoscopic Retrograde Cholangiopancreatography in Patients With Biliary Obstruction. Am J Gastroenterol. 2023. PMID: 37713527. doi:10.14309/ajg.0000000000002495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。